ACAD

Acadia Pharmaceuticals Inc.
Data: 2026-03-30
$21.07
Price
1.54%
Change
$28.35
52W High
$13.4
52W Low

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Quick Stats
Mar 30, 2026

54.1

AI Score

HOLD

0.88

Volume Ratio

May 06, 2026

Next Earnings

13

+ve Days (30d)

17

-ve Days (30d)

ACAD Stock Summary

Last updated Mar 30, 2026

ACAD is currently trading at $21.07, positioned below its 200-day moving average of $23.73, suggesting bearish momentum. The stock has a 52-week range of $13.4 to $28.35.

Technical Analysis: The 50-day moving average stands at $23.37, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 42.508, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.051, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates ACAD at 54.1/100 with a HOLD recommendation.

ACAD (Acadia Pharmaceuticals Inc.) Indicators

Last updated Mar 30, 2026

Indicator Value
RSI(14) 42.508
CMF (20) -0.051
ROC (10) -1.496
ADX (14) 29.373
Indicator Value
MACD (12,26,9) -0.701
AROONOSC (14) -50.0
WILLAMS %R (14) -54.615
MFI (14) 44.935
ACAD Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

ACAD Price vs Max Options Open Interest
ACAD Max Change In Options Open Interest

ACAD Options - Sort by Max open Interest (near term)

30th March 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

ACAD Daily Out of Money Options - Sort by Max open Interest (near term)

30th March 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

ACAD Daily In the Money Options - Sort by Max open Interest (near term)

30th March 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

ACAD Most Active Options by Volume(near term)

30th March 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Acadia Pharmaceuticals Inc. is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

ACAD Moving Averages Analysis

ACAD (Acadia Pharmaceuticals Inc.) Simple Moving Averages

Moving Averages are last updated Mar 30, 2026

Days MA
10 20.99
20 21.54
30 22.38
50 23.37
100 24.49
200 23.73

ACAD Fundamental Analysis

P/E (Forward) 47.619
P/E (Trailing) 9.0217
Market Cap ($) 3.5 billion
Earnings/Share ($) 2.3
Net Proft Margin (%) 0.3649
Dividend/Share ($) --
EPS Estimate Current Year ($) 0.4965
EPS Estimate Next Year ($) 0.9046
WallStreet Target Price ($) 31.85
Most Recent Quarter